Thus, our data identify SAMHD1 expression as a biomarker of resistance to doxorubicin and PARP inhibitor in DLBCL cells and as a unique prognostic biomarker for outcome in patients with advanced stage higher risk DLBCL. The gene discussed is SAMHD1; the disease is diffuse large B-cell lymphoma.